Annals of Oncology Advance Access published online on May 13, 2008
Annals of Oncology, doi:10.1093/annonc/mdn293
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org
letter to the editor |
Insulin receptor substrate protein 53 (IRSp53) as a binding partner of antimetastasis molecule NESH, a member of Abelson interactor protein family
| The first 10% of the full text of this article appears below. |
Involvement of NESH in cancer invasion and metastasis is now very important and interesting. In order to clarify the molecular mechanisms, we identified insulin receptor substrate protein 53 (IRSp53) as a partner of NESH utilizing a conventional yeast two-hybrid screen with a proline-rich domain of NESH as bait. The specific interaction was confirmed by coimmunoprecipitation assay and colocalization analysis in mammalian cells. The carboxyl-terminal SH3 domain of IRSp53 is responsible for the interaction with the proline-rich domain of NESH. NESH may play a critical role in regulating the actin cytoskeleton required
funding


1 Department of Environmental Health, Nara Women's University, Nara 630-8506
2 Department of Molecular Pathogenesis
3 Second Department of Internal Medicine, Nagoya University School of Medicine, Nagoya 466-8550
4 Department of Hematology/Oncology, Teikyo University School of Medicine, Tokyo, Japan
* (E-mail: smatsuda@cc.nara-wu.ac.jp)